Physician profile
David Mcintosh
NPI 1710050869
$545.94
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $203 · 2021: $61.88 · 2022: $37.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $192.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $146.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $61.70 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.62 | 2019 | |
| Genentech USA, INC. | $14.54 | 2019 | |
| Eisai INC. | $12.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.